Market research
LINCOLN.NSE Lincoln Pharmaceuticals Limited
NSE INR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12B
- P/E ratio
- 12.95
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.4
Community
Investor discussion
1 comment
Sign in to join the LINCOLN.NSE discussion.
5 years, 5 months ago
Lincoln Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 35.1% above its 200 day moving average.
From a valuation standpoint, the stock is 77.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Lincoln Pharmaceuticals Limited's total revenue rose by 16.5% to $1B since the same quarter in the previous year.
Its net income has increased by 23.6% to $135M since the same quarter in the previous year.
Finally, its free cash flow grew by 43.3% to $454M since the same quarter in the previous year.
Based on the above factors, Lincoln Pharmaceuticals Limited gets an overall score of 5/5.